推动阿尔茨海默病生物标志物临床实践中的标准化报告
本文讨论阿尔茨海默病脑脊液及血液生物标志物报告实践中的异质性,提出标准化临床神经化学报告的结构化框架,涵盖报告标识、分析信息、方法平台、单位、参考区间与决策阈值、分析前及质量因素、循证解释性注释等要素,并强调多标志物结构化解读与临床情境结合。
要点
- 生物标志物报告需标准化以实现跨实验室可比性。
- 标准化报告应包含分析信息、单位、阈值及解释性注释。
- 结构化多标志物解读需结合临床情境。
核心结论
- 标准化报告是实验室质量的关键组成部分,可确保分析进展转化为一致、临床有意义且可互操作的信息。
研究设计与样本
- 本文为综述/观点文章,讨论阿尔茨海默病生物标志物标准化报告原则并提出结构化框架。
主要发现
- 尽管存在国际质量标准,报告实践在术语、测量单位、分析描述、参考框架和解释性注释方面仍存在显著异质性。
- 异质性限制了实验室间可比性,并可能影响临床决策。
关键数值与推荐
- 标准化报告应包括报告标识、分析信息、分析方法与平台说明、标准化测量单位、参考区间与临床决策阈值的适当使用、分析前及质量相关因素记录、循证解释性注释。
临床怎么用
- 临床实验室应采用结构化报告框架,结合临床情境进行多标志物解读,并促进医疗系统互操作性与纵向监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cerebrospinal fluid biomarkers, and more recently blood-based biomarkers, are playing a pivotal role in reshaping the clinical management of neurodegenerative diseases, supporting early detection, biological diagnosis, patient stratification, prognostic assessment, therapeutic decision-making, and longitudinal disease monitoring. To effectively support clinical decision-making, biomarker measurements must be communicated in a standardized, transparent, and clinically interpretable manner. Despite international quality standards, considerable heterogeneity persists in reporting practices, including differences in terminology, units of measurement, analytical descriptions, reference frameworks, and interpretative comments, limiting comparability across laboratories and potentially affecting clinical decision-making. In this article, we discuss the principles of harmonized reporting for Alzheimer's disease biomarkers and propose a structured framework for standardized clinical neurochemistry reports. We describe the essential components of a harmonized report, including report identification, analytical information, specification of analytical method and platform, standardized units of measurement, appropriate use of reference intervals and clinical decision thresholds, documentation of pre-analytical and quality-related factors, and evidence-based interpretative comments. We further discuss the importance of structured multimarker interpretation and the need to contextualize biomarker findings within the clinical scenario. Finally, we examine the role of harmonized reporting in promoting interoperability across healthcare systems, facilitating longitudinal patient monitoring, supporting electronic health records and standardized terminologies, and enabling artificial intelligence-driven clinical decision support. As neurodegenerative disease diagnostics continue to evolve and novel biomarkers and technologies emerge, harmonized reporting should be regarded as a critical component of laboratory quality, ensuring that analytical advances translate into consistent, clinically meaningful, and interoperable information that ultimately improves patient care.
引用
- Agnello L, Pilotto A, Gaetani L, et al. Toward harmonized reporting of Alzheimer's disease biomarkers in clinical practice. Clin Chem Lab Med. 2026. PMID: 42683894. doi:10.1515/cclm-2026-1113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。